Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
103.082,37
-1,00%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ LENZ Therapeutics Inc (LENZ) LENZ Therapeutics Inc (LENZ) Notizie

LENZ

LENZ Therapeutics (LENZ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LENZ
DataOraFonteTitoloSimboloCompagnia
12/11/202414:00GlobeNewswire Inc.LENZ Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LENZLENZ Therapeutics Inc
06/11/202413:00GlobeNewswire Inc.LENZ Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:LENZLENZ Therapeutics Inc
30/10/202413:00GlobeNewswire Inc.LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024NASDAQ:LENZLENZ Therapeutics Inc
28/10/202402:00GlobeNewswire Inc.CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100NASDAQ:LENZLENZ Therapeutics Inc
21/10/202414:00GlobeNewswire Inc.LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of PresbyopiaNASDAQ:LENZLENZ Therapeutics Inc
30/09/202414:00GlobeNewswire Inc.LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical ConferencesNASDAQ:LENZLENZ Therapeutics Inc
14/08/202422:05GlobeNewswire Inc.LENZ Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:LENZLENZ Therapeutics Inc
12/08/202414:00GlobeNewswire Inc.LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaNASDAQ:LENZLENZ Therapeutics Inc
07/08/202422:01GlobeNewswire Inc.LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:LENZLENZ Therapeutics Inc
15/07/202414:00GlobeNewswire Inc.LENZ Therapeutics Announces $30 Million Investment from Ridgeback CapitalNASDAQ:LENZLENZ Therapeutics Inc
10/06/202414:00GlobeNewswire Inc.LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024NASDAQ:LENZLENZ Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.LENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:LENZLENZ Therapeutics Inc
21/05/202414:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LENZLENZ Therapeutics Inc
09/05/202422:18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LENZLENZ Therapeutics Inc
08/05/202423:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LENZLENZ Therapeutics Inc
08/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LENZLENZ Therapeutics Inc
08/05/202422:01GlobeNewswire Inc.LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:LENZLENZ Therapeutics Inc
01/05/202422:01GlobeNewswire Inc.LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024NASDAQ:LENZLENZ Therapeutics Inc
03/04/202413:00Business WireLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsNASDAQ:LENZLENZ Therapeutics Inc
02/04/202422:01Business WireLENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsNASDAQ:LENZLENZ Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LENZ

La tua Cronologia

BOV
RSUL3T
RIO SULENSE
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network